In our cohort, the MGMT promoter methylated gliomas (n = 10) had a higher overall mean APTw signal intensity of 2.38% compared to 1.92% for non-methylated gliomas (n = 3), albeit, the differences in levels of APTw signals could not be statistically analysed due to insufficient number of patients (Table 1). The gene discussed is MGMT; the disease is central nervous system cancer.